Erythropoiese und Serumerythropoietinkonzentration vor und nach Nierenallotransplantation

@article{Keusch1989ErythropoieseUS,
  title={Erythropoiese und Serumerythropoietinkonzentration vor und nach Nierenallotransplantation},
  author={Gerald T Keusch and Armin Kurtz and J{\"o}rg Fehr and K. U. Eckardt and Dieter W Frei and Christian H. Bauer and Ulrich Binswanger},
  journal={Nephron},
  year={1989},
  volume={51},
  pages={29-33}
}
: Hematological parameters and serum erythropoietin (EPO) levels were measured before and sequentially after grafting in 50 consecutive cadaver renal transplant recipients. EPO was estimated using a sensitive radioimmunoassay. Values for nonanemic controls were 15-25 mU/ml. Mean hematological values before transplantation were as follows: hemoglobin 9.7 +/- 2.4 g/dl; hematocrit 29 +/- 8%; corrected reticulocytes count 15 +/- 8% and EPO 29 +/- 23 (11-131) mU/ml. In the entire studied population… 
View via Publisher
epub.uni-regensburg.de
6 Citations

6 Citations

Citation Type

Citation Type

Intrarenal extramedullary erythropoiesis in renal allograft fine-needle aspirates.
Epoetin (Recombinant Human Erythropoietin)
TLDR
Epoetin represents a significant therapeutic advance in the treatment of anaemia associated with chronic renal failure and should be considered a first option for patients following patients with preexisting hypertension, and in facilitating autologous blood donation.
Erythropoiesis and erythropoietin levels in renal transplant recipients
TLDR
Moderately increased blood levels of endogenous erythropoietin (Epo) usually induce complete restoration of renal anemia after successful kidney transplantation, but about 15% of recipients fail to exhibit the normal feedback regulation and develop a mostly transient post-transplant erythrocytosis.
Role of excretory graft function for erythropoietin formation after renal transplantation
TLDR
The kinetics of plasma immunoreactive EPO (irEPO) in patients with end‐stage renal disease undergoing renal allotransplantation (RTX) are determined and the role of renal excretory function for EPO formation is examined.
Role of excretory graft function for erythropoietin formation after renal transplantation
TLDR
The kinetics of plasma immunoreactive EPO (irEPO) in patients with end‐stage renal disease undergoing renal allotransplantation (RTX) are determined and the role of renal excretory function for EPO formation is examined.
Tissue Targeting of Angiotensin Peptides*
TLDR
Direct injection of an expression vector encoding such a fusion protein into rat cardiac ventricles results in a highly localized expression of atrial natriuretic peptide mRNA (an angiotensin responsive marker of cardiac hypertrophy), demonstrating the utility of this approach for local targeting of mature peptides to tissues in animal models.

References

SHOWING 1-10 OF 13 REFERENCES
Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency.
TLDR
Results suggest that inhibition of erythroid, but not granulocytic, progenitor cell formation, in addition to a relative erythropoietin deficiency, are the primary factors responsible for the anemia of chronic renal failure.
Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients.
TLDR
An inappropriately low serum erythropoietin level for the severity of anemia in uremic hemodialysis patients is suggested and greater availability of erymorphine results in more effective ERYthropoiesis, even in the Uremic environment.
Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure.
TLDR
Although serum immunoreactive erythropoietin levels are elevated above the normal range in dialysis patients, the response remains inadequate for the severity of the anemia, and it is the degree of serum inhibition of erythroid progenitor cell (CFU-E) formation in both CAPD and RDT patients which correlates with and possibly determines thedegree of anemia.
Erythropoietin titers in anemic, nonuremic patients.
TLDR
Ierythropoietin titers in these anemias appear to be determined primarily by the degree of anemia and not by any specific effect of these illnesses on the production of erythropOietin.
Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis.
TLDR
Observations indicate that CAPD removes inhibitors of erythropoiesis and human macrophage function in vitro, and are consistent with transport of inhibitory substances of high molecular weight into the peritoneal cavity.
EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease.
TLDR
The rise in hematocrit in CAPD patients is due to an increase in red cell mass and also to a decrease in plasma volume, which represents an improvement in renal anemia in these patients.
Correction of anaemia following renal transplantation: serial changes in serum immunoreactive erythropoietin, absolute reticulocyte count and red‐cell creatine levels
Summary. Improvement of erythropoiesis following successful human renal transplantation in eight patients was monitored by sequential measurements of haemoglobin, red‐cell creatine, absolute…
The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo.
TLDR
Dose-response effects, coupled with the identical erythropoietic response in normal and uremic sheep given the same amount of Ep-rich plasma, imply that there are no physiologically significant erythrocyte mass changes in uremia.
Release of erythropoietin from macrophages mediated by phagocytosis of crystalline silica.
TLDR
The optimal conditions required for release of Ep from silica-treated spleen macrophages are described and the reduction to background Ep levels when reduced glutathione, alpha tocopherol (vitamin E), and alpha-thioglycerol is discussed in terms of a possible mechanism of silica action.
...
1
2
...